The NDA regulatory consultancy has appointed Claes Buxfeldt, a former executive at AstraZeneca Plc, as HTA director and a member of its advisory board. In this position, he will advise the consultancy’s clients on health technology assessment. At AstraZeneca he was global pricing and reimbursement director for the company’s respiratory and inflammation businesses.
NDA announced the appointment on 6 March 2018.
Copyright 2018 Evernow Publishing Ltd.